Synapse - Craig Moskowitz

Search Within

Craig Moskowitz

Results (407)

BCL6 and outcome in diffuse large B-cell lymphoma: A work in progress

Journal Article

Moskowitz, C. H.; Hamlin, P. A.; Zelenetz, A. D.
Blood (2007)

Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma

Journal Article

Moskowitz, C. H.; Hamlin, P. A.; Gabrilove, J.; Bertino, J. R.; Portlock, C. S.; Straus, D. J.; Gencarelli, A. N.; Nimer, S. D.; Zelenetz, A. D.
Annals of Oncology (2007)

Fulltext@MSK | Save

An evidence-based approach to the management of Hodgkin's lymphoma

Book Section

Moskowitz, C. H.
In Chang, A. E.; Hayes, D. F.; Pass, H. I.; Stone, R. M.; Ganz, P. A.; Kinsella, T. J.; Schiller, J. H.; Strecher, V. J. (Eds.) Oncology: An Evidence-Based Approach (2006)

Fulltext@MSK | Save

Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-Cell lymphomas: Results of the MSKCC phase I/II experience

Meeting Abstract

O'Connor, O. A.; Hamlin, P. A.; Gerecitano, J.; Portlock, C. S.; Noy, A.; Moskowitz, C.; Straus, D. J.; Sarasohn, D.; Dumitrescu, O.; Pappanicholaou, J.; more...
Blood (2006)

Fulltext@MSK | Save

Early phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies

Meeting Abstract

O'connor, O.; Hamlin, P.; Neylon, E.; Moskowitz, C.; Portlock, C.; Noy, A.; Sirotnak, F.; Zelenetz, A.; Mould, D.; Horwitz, S.
EJC Supplements (2006)

Fulltext@MSK | Save

Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL

Meeting Abstract

Moskowitz, C.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; O'Connor, O. A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Lessac-Chenen, S.; Weaver, A.; more...
Blood (2006)

Fulltext@MSK | Save

FDG-PET scans as a staging study for T-cell lymphomas: High rates of positivity do not result in frequent changes in stage

Meeting Abstract

Horwitz, S. M.; Foss, F.; Goldfarb, S.; Molina, A.; Hamlin, P. A.; O'Connor, O. A.; Cammarata, M.; Moskowitz, C. H.; Zelenetz, A. D.
Blood (2006)

Fulltext@MSK | Save

Relapsed and refractory primary mediastinal diffuse large B-cell lymphoma: Outcome with ICE-based treatment

Meeting Abstract

Hamlin, P. A.; Dickson, M.; Kewalramani, T.; Horwitz, S. M.; Portlock, C. S.; Yahalom, J.; Zelenetz, A. D.; Moskowitz, C. H.
Blood (2006)

Fulltext@MSK | Save

Long-term outcomes of survivors of autologous hematopoietic-cell transplantation for refractory and relapsed Hodgkin's disease

Meeting Abstract

Goodman, K. A.; Serrano, V.; Riedel, E. R.; Gulati, S.; Moskowitz, C. H.; Yahalom, J.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders

Meeting Abstract

Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; more...
Blood (2006)

Fulltext@MSK | Save